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Summary
Objective: The values of bone mineral density (BMD) were compared in postmenopausal 
women with and without breast cancer. Methods: A cross-sectional study was conducted, 
including 51 breast cancer survivors (BCS) and 71 women without breast cancer, who were 
non-users of hormone therapy, tamoxifen, or aromatase inhibitors. BMD T-scores and mea-
surements in grams per centimeter squared (g/cm2) were obtained at the femoral neck, tro-
chanter, Ward’s triangle, and lumbar spine. Osteopenia and osteoporosis were grouped and 
categorized as abnormal BMD. Unconditional logistic regression analysis was used to esti-
mate the odds ratios (OR) of abnormal BMD values as measures of association, with 95% con-
fidence intervals (CIs), adjusting for age, years since menopause, parity, and body mass index 
(BMI). Results: The mean age of the women with and without breast cancer was 54.7 ± 5.8 
years and 58.2 ± 4.8 years (p < 0.01), respectively. After adjusting for age, parity and BMI, 
abnormal BMD at the femoral neck (adjusted OR: 4.8; 95% CI: 1.5-15.4), trochanter (adjusted 
OR:  4.6; 95% CI:  1.4-15.5), and Ward’s triangle (adjusted OR:  4.5;  95% CI:  1.5-12.9) were 
significantly more frequent in postmenopausal BCS than in women without breast cancer. 
Postmenopausal BCS had a significantly lower mean BMD at the trochanter (0.719 vs. 0.809 
g/cm2, p < 0.01) and at the Ward’s triangle (0.751 vs. 0.805 g/cm2, p = 0.03). Conclusion: The 
prevalence of abnormal BMD was higher in postmenopausal BCS than in postmenopausal 
women without breast cancer. Bone health requires special vigilance and the adoption of in-
terventions should be instituted early to minimize bone loss in BCS.
Keywords: Breast cancer; menopause; bone loss; abnormal bone mineral density.
reSumo
Densidade mineral óssea em mulheres na pós-menopausa com e 
sem câncer de mama
Objetivo: Comparar a densidade mineral óssea (DMO) de mulheres na pós-menopausa com e sem cân-
cer de mama. Métodos: Conduziu-se estudo de corte transversal, incluindo 51 mulheres com câncer de 
mama e 71 mulheres sem câncer de mama, não usuárias de terapia hormonal, tamoxifeno ou de inibido-
res da aromatase. Avaliou-se a DMO, em T-score e em gramas por centímetro quadrado (g/cm²), no colo 
do fêmur, trocânter, triângulo de Wards e na coluna lombar. Osteopenia e osteoporose foram agrupadas 
e categorizadas como DMO alterada. Utilizou-se a análise de regressão logística não condicional para 
estimar o odds ratios (OR) de DMO alterada como medida de associação, com intervalo de confiança de 
95% (IC 95%), ajustando-se por idade, anos de menopausa, paridade e índice de massa corpórea (IMC). 
Resultados: A média de idade de mulheres com e sem câncer de mama foi 54,7 ± 5,8 anos e 58,2 ± 4,8 
anos (p < 0,01), respectivamente. Após ajustar por idade, paridade e IMC, DMO alterada no colo do 
fêmur (OR ajustado: 4,8; IC 95%: 1,5-15,4), trocânter (OR ajustado: 4,6; IC 95%: 1,4-15,5) e no triângulo 
de Wards (OR ajustado: 4,5; IC 95%: 1,5-12,9) foi mais frequente em mulheres com câncer de mama. 
Mulheres com câncer de mama apresentaram significativamente menor média de DMO no trocânter 
(0,719 vs. 0,809 g/cm2, p < 0,01) e no triângulo de Wards (0,751 vs. 0,805 g/cm2, p = 0,03). Conclusão: A 
prevalência de DMO alterada foi maior em mulheres na pós-menopausa com câncer de mama. A saúde 
óssea requer vigilância especial e a adoção precoce de intervenções para minimizar a perda óssea de 
mulheres com câncer de mama.
Unitermos: Câncer de mama; menopausa; perda óssea; densidade mineral óssea alterada.
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IntroductIon
Breast cancer is the most frequently diagnosed cancer 
in women worldwide, representing 23% (1.38 million) 
of the total new cancer cases in 20081. Breast cancer is 
primarily a disease of postmenopausal women2. In the 
postmenopause, there is a reduction in serum estrogen 
levels leading to bone loss. Estrogen plays an important 
role in skeletal maintenance due to its osteoprotective 
action3. In this context, postmenopausal status is a major 
risk factor for low bone mineral density (BMD)4.
Previous studies have demonstrated a relationship 
between a higher BMD and a higher risk for post-
menopausal breast cancer5,6. Although the mechanism 
of this relationship is not fully understood, cumulative 
exposure to estrogen may play a role5. BMD may be a 
predictor for breast cancer risk, but breast cancer survi-
vors (BCS) can also develop bone loss related to cancer 
treatment7,8. Chemotherapy-induced ovarian failure7,8, 
aromatase inhibitor use9,10, and a potential direct toxic 
chemotherapy effect on bone tissue11 may induce and 
intensify bone loss in BCS. Tamoxifen use is associated 
with significant bone loss in premenopausal BCS. How-
ever, tamoxifen exerts a bone-protective action in wom-
en with early menopause induced by chemotherapy12.
Premenopausal women with breast cancer undergo-
ing chemotherapy with preserved ovarian function do 
not have a significant reduction in bone mass7,8. How-
ever, those who develop amenorrhea have a rapid and 
significant bone loss7,8. Menopausal hormone therapy 
may be indicated for the prevention of bone loss13, and 
many women on hormone therapy at the time of breast 
cancer diagnosis are instructed to discontinue its use2. 
Discontinuation of hormone therapy is based on an in-
creased risk of breast cancer recurrence14. This group of 
factors contributes to increased bone loss in postmeno-
pausal BCS.
Previous studies have investigated BMD in post-
menopausal survivors of breast cancer15-22. However, 
few studies have evaluated a group of women without 
breast cancer for comparison18,19,22. In one study, mean 
BMD values in postmenopausal BCS were similar to 
those in population-based non-BCS18. In contrast, the 
prevalence of osteoporosis in another study was 27.2% 
in BCS and 19.4% in women without breast cancer19. 
Furthermore, it was demonstrated that postmeno-
pausal BCS had a higher fracture risk than cancer-free 
women20.
Despite these findings, a notable proportion of 
postmenopausal BCS have undiagnosed abnormal 
BMD15,16,19. Considering these aspects, the present study 
was conducted aiming to compare BMD in Brazilian 
postmenopausal women with and without breast cancer
methodS
Patients
Participant selection has been previously described in de-
tail23. The current sample was derived from a study that in-
vestigated menopause symptoms, sexual activity, quality of 
life, some cardiovascular risk factors, and BMD in BCS23. 
The present study focused on the findings of BMD in post-
menopausal women with and without breast cancer.
A cross-sectional study of women undergoing routine 
follow-up care was conducted in the Women’s Hospital 
of the School of Medicine of the Universidade Estadual 
de Campinas, Brazil. Patients who met the inclusion cri-
teria were invited to participate in the study during out-
patient consultation. Women aged 45-65 years, who were 
non-users of hormone therapy or tamoxifen in the last six 
months, and who had no history of other malignancies 
were invited. Only postmenopausal women who complet-
ed oncology treatment were included in this study. None 
of the BCS were using aromatase inhibitors. A total of 187 
women were invited to participate in the study, 100 BCS 
and 87 without breast cancer. Among the BCS, three re-
fused to participate in the study due to lack of time, 22 were 
undergoing oncology treatment, 12 were premenopausal, 
seven had no knowledge of time since menopause, and five 
did not have bone density measurements. Among women 
without breast cancer, two refused to participate in the 
study due to lack of time, four were premenopausal, and 
ten had no knowledge of time since menopause. Therefore, 
122 postmenopausal women, 51 with breast cancer and 71 
without breast cancer, constituted the present study sample.
Participants responded to an interview that assessed 
sociodemographic characteristics, including age, race/
ethnicity, age at menarche, parity, smoking, age at meno-
pause, and years since menopause. Clinical characteristics 
included body mass index (BMI) in kilograms per square 
meter (kg/m2), time since breast cancer diagnosis, type of 
surgery, tumor stage, chemotherapy, and radiotherapy. This 
study was approved by the institutional review board; all 
participants signed an informed consent.
Bone Mineral Density MeasureMent
BMD tests were ordered in the initial interview with the 
patient. BMD in grams per centimeter squared (g/cm2) was 
measured at the femoral neck, trochanter, Ward’s triangle, 
and the lumbar spine (L2-L4; anteroposterior plane) us-
ing a Lunar DPX device (DXA; Lunar DPX, Madison, WI, 
USA). BMD values were also expressed as T-scores, using 
the World Health Organization criteria24: normal: T-score 
≥ -1 standard deviation (SD); osteopenia: T-score between 
-1 and -2.5 SDs; osteoporosis: T-score ≤ -2.5 SDs. In this 
study, a BMD T-score < -1 SD was considered abnormal 
(osteopenia and osteoporosis grouped together).
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statistiCal analysis
The means of descriptive continuous variables were com-
pared between women with and without cancer using 
Student’s t-test for independent samples. The frequencies 
of binary variables were compared by Fisher’s exact test. 
Unconditional logistic regression analysis25 was used to es-
timate the odds ratios (OR) of abnormal BMD as measures 
of association, with 95% confidence intervals (CIs). In 
these models, the independent binary variable was breast 
cancer (with cancer/without cancer), and the dependent 
binary variable was BMD, classified as normal or abnor-
mal. The ORs were estimated as measures of the associa-
tion between cancer and abnormal BMD in the femoral 
neck, trochanter, Ward’s triangle and lumbar spine with 
and without adjustment for age, parity, years since meno-
pause, and BMI in quartiles. When age and years since 
menopause were considered, regression models could not 
be fitted because of the strong collinearity between these 
variables. The ORs adjusted for age, parity, and BMI, and 
adjusted for years since menopause, parity, and BMI were 
estimated. When bone density (g/cm2) was regarded as a 
continuous variable, linear regression models26 were used 
to compare the population means between women with 
and without cancer adjusting for covariates. All analyses 
were performed using the SAS version 9.2 software. The 
significance level was set at 5%.
reSultS
The mean age of women with breast cancer was 54.7 ± 5.8 
years and 58.2  ±  4.8 years for those without breast can-
cer (p < 0.01). The mean BMI was 27.5 ± 5.2 kg/m2 and 
30.2 ± 5.7 kg/m2 for women with and without breast can-
cer (p < 0.01), respectively. The mean age at menopause 
was 47.1  ±  5.0 years for women with breast cancer and 
47.4 ± 4.9 years for women without breast cancer (p = 0.98). 
Bone density measurement was performed from one to 
two months after the first interview. Other characteristics 
are shown in Table 1. In the breast cancer group, the mean 
time since breast cancer diagnosis was 67.9 ± 53.1 months. 
A little over half of the postmenopausal BCS (52.9%) 
underwent mastectomy, and 47.1% underwent breast-
conserving therapy. Approximately 72% of women under-
went chemotherapy, 76.5% underwent radiation therapy, 
and 60.8% underwent chemotherapy and radiation ther-
apy. Distribution according to tumor stage was (n, %): 0 
(4, 7.8%), I (7, 13.7%), II (31, 60.8%), and III (9, 17.7%).
In the unadjusted analysis, the results in Table 2 show 
that postmenopausal BCS had a significantly higher preva-
lence of abnormal BMD at the femoral neck, trochanter, 
and Ward’s triangle than women without breast cancer. 
After adjusting for age, parity, and BMI, abnormal BMD 
at the femoral neck (adjusted OR: 4.8; 95% CI: 1.5-15.4), 
trochanter (adjusted OR:  4.6;  95%  CI:  1.4-15.5), and 
Ward’s triangle (adjusted OR: 4.5; 95% CI: 1.5-12.9) was 
significantly more frequent in postmenopausal BCS than 
in women without breast cancer. After adjusting for years 
since menopause, parity, and BMI, the prevalence of ab-
normal BMD at the femoral neck, trochanter, and Ward’s 
triangle remained significantly higher in postmenopausal 
BCS. In unadjusted and adjusted analysis, there was no 
significant difference in the prevalence of abnormal lum-
bar spine (L2-L4) BMD between BCS and women without 
breast cancer.
Figure 1 displays the mean BMD (g/cm2) of post-
menopausal BCS and women without breast cancer. On 
analysis adjusted for age, parity, and BMI, BCS showed 
a significantly lower mean BMD at the trochanter 
(0.719 vs. 0.809 g/cm2, p < 0.01) and Ward’s triangle (0.751 
vs. 0.805 g/cm2, p = 0.03). After adjusting for years since 
menopause, parity, and BMI, BCS had a significantly lower 
mean BMD at the trochanter (p < 0.01), and Ward’s tri-
angle (p = 0.03).
dIScuSSIon
This study aimed to compare BMD in women with and 
without breast cancer. Few studies have investigated BMD 
in postmenopausal BCS, in comparison to a group of post-
menopausal women without breast cancer. Based on BMD 
Characteristics With cancer (n = 51) Without cancer (n = 71) p-value
Age (years) 54.7 ± 5.8 58.2 ± 4.8 < 0.01a
Age at menarche (years) 13.1 ± 1.8 13.1 ± 1.9 0.85a
Body mass index (kg/m2) 27.5 ± 5.2 30.2 ± 5.7 < 0.01a
Age at menopause (years) 47.1 ± 5.0 47.4 ± 4.9 0.98a
Years since menopause 7.4 ± 5.2 10.6 ± 5.3 < 0.01a
Race (% white women) 21.6 32.4 0.22b
Parity (% nulliparous) 17.7 4.2 0.03b
Smokers (%) 13.7 5.6 0.22b
Data are expressed as mean ± SD unless otherwise specified. a Student’s t-test for independent samples; b Fisher’s exact test.
Table 1 – Sociodemographic and clinical features of postmenopausal women with and without breast cancer
673_678_12_049_Bone.indd   675 30/11/12   10:37
Délio Marques ConDe et al.
676 Rev Assoc Med Bras 2012; 58(6):673-678
T-scores, it was observed that abnormal BMD at the femo-
ral neck, trochanter, and Ward’s triangle was significant-
ly more frequent in BCS than in women without breast 
cancer. Furthermore, BCS had a significantly lower mean 
BMD (g/cm2) at the trochanter and Ward’s triangle.
In this case study, it was observed that the prevalence 
of abnormal BMD in postmenopausal BCS was higher at 
the Ward’s triangle (59.5%), and lumbar spine (56.9%). In 
another study, including only postmenopausal BCS with 
a mean age of 54 years and 36.6% of tamoxifen users, it 
was observed that 56.3% of the participants had abnormal 
BMD at the lumbar spine15. The findings of these authors15 
were similar to the present results regarding the high prev-
alence rate of abnormal BMD at the lumbar spine (56.9%), 
although the participants of the present cohort were non-
users of tamoxifen. Other studies have also reported a high 
frequency of abnormal BMD at the lumbar spine19,21,22. 
The lumbar spine and Ward’s triangle have a high con-
tent of trabecular bone. A higher frequency of abnormal 
BMD at these bone sites may be related to a greater sensi-
tivity of trabecular bone to estrogen deficiency27. This is a 
characteristic of postmenopausal women who do not use 
hormone therapy.
Few studies comparing BMD between postmenopaus-
al BCS and women without breast cancer have been iden-
tified18,19,22. Based on cross-sectional data18, BMD Z-scores 
of BCS were investigated. This study found that postmeno-
pausal patients who had not received adjuvant therapy 
had higher whole body BMD compared to age-matched 
women. Furthermore, the authors reported that hip and 
spine BMD measurements in postmenopausal BCS were 
similar to those in a population-based sample without 
breast cancer, suggesting that the treatment had caused no 
major deleterious effect on the BMD of BCS18. However, 
a retrospective study found that women who were post-
menopausal at the time of breast cancer diagnosis and re-
ceiving adjuvant chemotherapy had lower BMD Z-scores 
at the total hip, femoral neck, trochanter, and lumbar spine 
than those who had not received chemotherapy17, indicat-
ing a potential detrimental effect of adjuvant therapy on 
the BMD of postmenopausal women.
In another study22, BMD was compared between a 
BCS group with chemotherapy-induced amenorrhea and 
a premenopausal control group without breast cancer. 
Site
With cancer
n (%)
Whitout cancer
n (%)
Crude OR
(95% CI)
Adjusted ORa
(95% CI)
Adjusted ORb
(95% CI)
Femoral neck
Normal 32 (62.8) 57 (80.3) 1.00 1.00 1.00
Abnormal 19 (37.2) 14 (19.7) 2.4 (1.1-5.5) 4.8 (1.5-15.4) 3.8 (1.2-11.5)
Trochanter
Normal 25 (59.5) 47 (85.5) 1.00 1.00 1.00
Abnormal 17 (40.5) 8 (14.5) 4.0 (1.5-10.5) 4.6 (1.4-15.5) 4.6 (1.3-15.1)
Ward’s triangle
Normal 17 (40.5) 34 (61.8) 1.00 1.00 1.00
Abnormal 25 (59.5) 21 (38.2) 2.4 (1.0-5.4) 4.5 (1.5-12.9) 3.8 (1.3-10.7)
Lumbar spine (L2-L4)
Normal 22 (43.1) 40 (56.3) 1.00 1.00 1.00
Abnormal 29 (56.9) 31 (43.7) 1.7 (0.8-3.5) 1.2 (0.5-2.9) 1.5 (0.6-3.5)
SD, standard deviation; OR, odds ratio; CI, confidence interval, a OR estimates adjusted for age, parity and body mass index in quartiles; 
b OR estimates adjusted for years since menopause, parity and body mass index in quartiles.
Table 2 – Comparison of prevalence of abnormal bone mineral density (T-score < - 1 SD) of postmenopausal women with 
and without breast cancer
Figure 1 – Comparison of mean bone mineral density 
(g/cm2) in postmenopausal women with and without breast 
cancer.
a Adjusted for age, parity and body mass index in quartiles.
b Adjusted for years since menopause, parity and body mass index in quartiles.
 n 71 51
 Mean 0.943 0.900
 SD 0.103 0.123
p = 0.08 (a), p = 0.05 (b)
with cancer without cancer
  55 42
  0.809 0.719
  0.112 0.117
p < 0.01 (a), p < 0.01 (b)
with cancer without cancer
  55 42
  0.805 0.751
  0.124 0.148
p = 0.03 (a), p = 0.03 (b)
with cancer without cancer
  71 51
  1.090 1.060
  0.162 0.128
p = 0.58 (a), p = 0.64 (b)
with cancer
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The authors of this study observed that significantly more 
BCS had low spine BMD based on T-scores22. In the Wom-
en’s Health Initiative Observational Study (WHI-OS), data 
on the prevalence of low bone mass was reported in a large 
cohort of postmenopausal BCS, compared to cancer-free 
women19. In the WHI-OS, the frequency of osteoporosis 
was 27.2% in postmenopausal BCS and 19.4% in cancer-
free women. A comparison of BMD T-scores in post-
menopausal BCS and in women with no history of breast 
cancer, adjusting for covariables, except menopausal hor-
mone therapy, showed BCS with a significantly higher 
prevalence of osteoporosis in the total hip, total body, and 
at any site19. In the present study, the prevalence of abnor-
mal BMD T-scores at the femoral neck, trochanter, and 
Ward’s triangle was higher in BCS in adjusted and unad-
justed analyses. The mean BMD (g/cm2) at the trochanter 
and Ward’s triangle was higher among postmenopausal 
non-BCS, adjusting for potential confounding variables 
(age, years since menopause, parity, BMI). In the WHI-
OS, when menopausal hormone therapy was added as a 
covariate, the difference in the prevalence of osteoporosis 
between women with and without breast cancer was no 
longer significant19. Participants in the present study were 
not using hormone therapy, thus it was not possible to ad-
just for this variable.
Differences observed between the present findings and 
results of other studies may be related to the age differ-
ence between the participants, bone sites investigated, and 
variables evaluated. In the WHI-OS, a low BMD and high 
prevalence of osteoporosis in BCS occurred, especially be-
cause of lower hormone therapy use by these women19. The 
present study included women who did not take tamoxi-
fen or aromatase inhibitors, since the aim at the time of 
study design was to gain knowledge about BMD in BCS 
who were not receiving any hormone therapy.
From the present findings and previous studies, it can 
be inferred that abnormal BMD is a concern for post-
menopausal BCS15-19,21,22. Despite these findings, 77.8% of 
the WHI-OS postmenopausal BCS had undiagnosed os-
teoporosis at baseline. Thus, a considerable proportion of 
BCS women had no diagnosis of abnormal BMD and con-
sequently did not receive therapy, as previously reported16.
The findings should be interpreted considering some 
limitations, such as the cross-sectional study design and 
a lack of information about chemotherapy regimen. The 
immunohistochemical profile of tumors in BCS, which 
could have allowed the investigation of a relationship 
between hormone receptor status and BMD, was not in-
cluded. Physical activity, and calcium, caffeine, and alco-
hol consumption were not investigated. However, there 
was inconsistent evidence of an association between cur-
rent physical activity or calcium intake and BMD in a 
systematic review4. In this review, there was fair evidence 
that current caffeine intake was not associated with BMD, 
and that moderate alcohol consumption was not associ-
ated with lower BMD4.
To the authors’ knowledge, this was the first study con-
ducted in Latin America investigating BMD in postmeno-
pausal BCS. The existence of a control group of women 
with similar menopausal status, i.e., postmenopausal 
women with no history of breast cancer, is highlighted. 
Despite some differences between both groups, the com-
parisons between BMD were adjusted for potential con-
founding variables.
The current guidelines of the American Society of 
Clinical Oncology recommend the use of aromatase in-
hibitors in postmenopausal BCS with hormone receptor-
positive tumors during adjuvant therapy as an initial treat-
ment, or sequential or extended treatment after tamoxifen 
use28. Although further studies are still required, a recent 
randomized, placebo-controlled, double-blinded trial in 
healthy postmenopausal women has demonstrated that 
exemestane reduced the relative incidence of invasive 
breast cancers by 65%29. This group of data suggests that 
the use of aromatase inhibitors will become increasingly 
more frequent. In this context, the prevalence of abnormal 
BMD in BCS may be higher in the future than in the pres-
ent study. In BCS, there is a need for increased vigilance of 
bone health, especially in postmenopausal women.
concluSIon
In conclusion, the authors believe that these results are of 
interest to healthcare professionals involved in the man-
agement of women with breast cancer. The prevalence of 
abnormal BMD was higher in postmenopausal BCS than 
in postmenopausal women without breast cancer. Bone 
health requires special vigilance and the adoption of inter-
ventions should be instituted early to minimize bone loss 
in BCS.
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